PISCATAWAY, N.J. – Camber Pharmaceuticals announces the addition of fosaprepitant for injection to their current portfolio.

Fosaprepitant for injection is indicated in adults for the prevention of:

• acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.

• delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Fosaprepitant for injection from Camber is available in 150 mg per Vial-Single Dose.